Xue Hua

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

S. Hendrix, G. Viardot, H. Moebius, 2022, Journal of Alzheimer's disease : JAD.